FDA Pharmacogenomics Guide Needs Process To Accept Biomarkers – PhRMA
Executive Summary
FDA should define a process to prospectively validate biomarkers for pharmacogenomic product approval, the Pharmaceutical Research & Manufacturers of America said in comments on an FDA draft guidance
You may also be interested in...
Pharmacogenomics Guidance Cites Benefits Of Voluntary Submissions
FDA's final pharmacogenomics guidance outlines the benefits of voluntary pharmaceutical industry submissions of genomic data to the agency
Pharmacogenomics Guidance Cites Benefits Of Voluntary Submissions
FDA's final pharmacogenomics guidance outlines the benefits of voluntary pharmaceutical industry submissions of genomic data to the agency
FDA Pharmacogenomics Advisory Committee Will Oversee Data Submissions
FDA is forming a pharmacogenomics advisory committee to handle voluntary genomic data submissions, Office of Clinical Pharmacology & Biopharmaceutics Director Lawrence Lesko, PhD, said